Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study
SHOUVAL, Roni; LABOPIN, Myriam; BONDI, Oriet al.
2015 • In Journal of Clinical Oncology, 33 (28), p. 3144-3152
[en] Purpose: Allogeneic hematopoietic stem-cell transplantation (HSCT) is potentiallu curative for acute leukemia (AL), but carries considerable risk. Machine learning algorithms, which are part of the data mining (DM) approach, may serve for transplantation-related mortality risk prediction. Patients and Methods: This work is a retrospective DM study on a cohort of 28,236 adult HSCT recipients from the AL registry of the European Group for Blood and Marrow Transplantation. The primary objective was prediction of overall mortality (OM) at 100 days after HSCT. Secondary objectives were estimation of nonrelapse mortality, leukemia-free survival, and overall survival at 2 years. Donor, recipient, and procedural characteristics were alalyzed. The alternating decision tree machine learning algorithm was applied for model development on 70 % of the data set and validated on the remaining data.
Disciplines :
Hematology
Author, co-author :
SHOUVAL, Roni
LABOPIN, Myriam
BONDI, Ori
MISHAN-SHAMAY, Hila
CICERI, Fabio
ESTEVE, Jordi
GIEBEL, Sebastian
GORIN, Norbert C.
SCHMID, Christoph
POLGE, Emmanuelle
ALJURF, Mahmoud
KROGER, Nicolaus
CRADDOCK, Charles
BACIGALUPO, Andrea
CORNELISSEN, Jan J.
BARON, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study
Publication date :
01 October 2015
Journal title :
Journal of Clinical Oncology
ISSN :
0732-183X
eISSN :
1527-7755
Publisher :
American Society of Clinical Oncology, Alexandria, United States - Virginia
Gooley TA, Chien JW, Pergam SA, et al: Reduced mortality after allogeneic hematopoieticcell transplantation. N Engl J Med 363: 2091-2101, 2010
Hamadani M, Craig M, Awan FT, et al: How we approach patient evaluation for hematopoietic stem-cell transplantation. Bone Marrow Transplantation 45: 1259-1268, 2010
Gratwohl A, Stern M, Brand R, et al: Risk score for outcome after allogeneic hematopoietic stem-cell transplantation: A retrospective analysis. Cancer 115: 4715-4726, 2009
Parimon T, Au DH, Martin PJ, et al: A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 144: 407-414, 2006
Sorror ML, Maris MB, Storb R, et al: Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 106: 2912-2919, 2005
Raimondi R, Tosetto A, Oneto R, et al: Validation of the hematopoietic cell transplantation-specific comorbidity index: A prospective, multicenter GITMO study. Blood 120: 1327-1333, 2012
Versluis J, Labopin M, Niederwieser D, et al: Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem-cell transplantation with AML in first complete remission. Leukemia 29: 51-57, 2015
Nakaya A, Mori T, Tanaka M, et al: Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto study group for cell therapy. Biol Blood Marrow Transplantation 20: 1553-1559, 2014
Barba P, Martino R, Perez-Simon JA, et al: Combination of the hematopoietic cell transplantation comorbidity index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-Toxicity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplantation 20: 66-72, 2014
Lauer MS, D'Agostino RB Sr: The randomized registry trial: The next disruptive technology in clinical research? N Engl J Med 369: 1579-1581, 2013
Shouval R, Bondi O, Mishan H, et al: Application of machine learning algorithms for clinical predictive modeling: A data-mining approach in SCT. Bone Marrow Transplantation 49: 332-337, 2014
Breiman L: Statistical modeling: The two cultures (with comments and a rejoinder by the author). Stat Sci 16: 199-231, 2001
Maroco J, Silva D, Rodrigues A, et al: Data mining methods in the prediction of dementia: A real-data comparison of the accuracy, sensitivity and specificity of linear discriminant analysis, logistic regression, neural networks, support vector machines, classification trees and random forests. BMC Res Notes 4: 299, 2011
Witten IH, Frank E, Hall MA: Data Mining: Practical Machine Learning Tools and Techniques (ed 3). Burlington, MA, Morgan Kaufmann, 2011
Gooley TA, Leisenring W, Crowley J, et al: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18: 695-706, 1999
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
MED-AB Forms Manual. http://www.ebmt.org/Contents/Data-Management/Registrystructure/MEDABdatacollectionforms/Documents/MED-ABForms Manual.pdf
Freund Y, Mason L: The alternating decision tree learning algorithm. ICML 99: 124-133, 1999
Rao VS, Kumar MN: A new intelligence-based approach for computer-Aided diagnosis of Dengue fever. IEEE Trans Inf Technol Biomed 16: 112-118, 2012
Takada M, Sugimoto M, Naito Y, et al: Prediction of axillary lymph node metastasis in primary breast cancer patients using a decision tree-based model. BMC Med Inform Decis Mak 12: 54, 2012
Takada M, Sugimoto M, Ohno S, et al: Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique. Breast Cancer Res Treat 134: 661-670, 2012
DeGroot MH, Fienberg SE: The comparison and evaluation of forecasters. Statistician 32: 12-22, 1983
Royston P, Moons KG, Altman DG, et al: Prognosis and prognostic research: Developing a prognostic model. BMJ 338: B604, 2009
Blanche P, Dartigues JF, Jacqmin-Gadda H: Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med 32: 5381-5397, 2013
Cornelissen JJ, Gratwohl A, Schlenk RF, et al: The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: An integrated-risk adapted approach. Nat Rev Clin Oncol 9: 579-590, 2012
Shimoni A, Hardan I, Shem-Tov N, et al: Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity. Leukemia 20: 322-328, 2006
Sorror M, Storer B, Sandmaier BM, et al: Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 112: 1992-2001, 2008
Frassoni F, Labopin M, Powles R, et al: Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation: Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Lancet 355: 1393-1398, 2000
Giebel S, Labopin M, Mohty M, et al: The impact of center experience on results of reduced intensity: Allogeneic hematopoietic SCT for AML-An analysis from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation 48: 238-242, 2012
Gratwohl A, Brand R, Niederwieser D, et al: Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol 29: 1980-1986, 2011
Corradini P, Zallio F, Mariotti J, et al: Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. J Clin Oncol 23: 6690-6698, 2005
Tallman MS, Dewald GW, Gandham S, et al: Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem-cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 110: 409-417, 2007
Gratwohl A: The EBMT risk score. Bone Marrow Transplantation 47: 749-756, 2012
Wingard JR, Majhail NS, Brazauskas R, et al: Long-Term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 29: 2230-2239, 2011
Binder H, Allignol A, Schumacher M, et al: Boosting for high-dimensional time-To-event data with competing risks. Bioinformatics 25: 890-896, 2009
Mogensen UB, Gerds TA: A random forest approach for competing risks based on pseudovalues. Stat Med 32: 3102-3114, 2013
Ward RA, Brier ME: Retrospective analyses of large medical databases: What do they tell us? J Am Soc Nephrol 10: 429-432, 1999
